SILu™MAb K4 Stable-Isotope Labeled Universal Monoclonal Antibody
SIGMA/MSQC7 - recombinant, expressed in CHO cells
Synonym: SILu™MAB Stable-Isotope Labeled Universal Monoclonal Antibody Standard human; IgG4 kappa; Isotopically labeled mAb LC/MS Standard; Mass Spectrometry Monoclonal Antibody Standard
Product Type: Chemical
SILu™MAb K4 Universal Antibody Standard, Cat. No. MSQC7 : Using optimized overlap with common sequences in the Fc region of candidate antibodies, SILu™MAb K4 provides universal utility, thus eliminating the need for production of candidate-specific internal standards.
| antibody product type | primary antibodies |
| assay | ≥90% (SDS-PAGE) |
| packaging | vial of 100 μg (± 10% Lot-specific vial content given on certificate of analysis) |
| Quality Level | 200  |
| recombinant | expressed in CHO cells |
| shipped in | wet ice |
| storage temp. | −20°C |
| Analysis Note: | Quantitative MRM settings provided (xls ) |
| Analysis Note: | SILuMAb K4 Heavy Chain EVQLVESGGGLVQPGGSLRLSCVAS SILuMAb K4 Light Chain QSALTQPRSVSGSPGQSVTISCTGT Target overlap areas are underlined Package size based on protein content determined by A280 using an extinction coefficient (E0.1%) of 1.4 |
| Application: | Multiplex Universal Peptide Quant Approach Using Microflow LC/MS/MS for Non-human Preclinical PK Study of Therapeutic Monoclonal Antibodies ( Webinar  )Applying Best-in-Class HPLC Column Technologies to the Analysis of Proteins and Biotherapeutics Using SILuMab ( Webinar ) |
| Features and Benefits: | Universal Peptide Sequence Location YGPPCPPCPAPEFLGGPSVFLFPPKPK Heavy Chain (IgG4 Stabilized) VVSVLTVLHQDWLNGK Heavy Chain (IgG1, IgG3, IgG4) GFYPSDIAVEWESNGQPENNYK Heavy Chain (IgG1, IgG4) TTPPVLDSDGSFFLYSR Heavy Chain (IgG4) SGTASVVCLLNNFYPR Light Chain (kappa) VDNALQSGNSQESVTEQDSK Light Chain (kappa) DSTYSLSSTLTLSK Light Chain (kappa) Underlined is a Serine-Proline substitution in the hinge region that is present in many human IgG4-based therapeutic monoclonal antibodies SILuMab has been validated as an internal standard for quantitation of relevant biotherapeutics in a complex biological matrix by MRM-based LC-MS/MS. • SILuMab yielded reproducible, linear curves from 0.1 μg/mL to 1000 μg/mL without enrichment or depletion. • Good agreement was observed between multiple peptides derived from the same target. • Label incorporation was determined to be >98% by mass spectrometry. • Sequence coverage was confirmed by peptide mapping. |
| Legal Information: | SILu is a trademark of Sigma-Aldrich Co. LLC |
| Legal Information: | This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont. |
| Physical form: | Supplied as a lyophilized powder containing phosphate buffered saline |
| Preparation Note: | Produced utilizing enriched media containing stable isotope labeled amino acids are 13C6, 15N4-labeled arginine and 13C6, 15N2-labeled lysine |
| Preparation Note: | SILuMab design is optimized to be used as an internal standard for quantitation of monoclonal antibodies as well as Fc-fusion therapeutics. Because of overlap with the common sequences in the Fc region with candidate antibodies, SILuMab provides universal utility, thus eliminating the need for production of candidate-specific internal standards. |
| Preparation Note: | SILuMab recovery is maximized when 0.1% formic acid is used for reconstitution of the lyophilized product. Reconstitution with other solvents may reduce recovery. Do not freeze after reconstitution. Procedure • Briefly centrifuge the vial at ~10,000 x g to collect the product at the bottom of the vial. • Add 500 μL of purified water containing 0.1% formic acid to the vial. • Mix the contents by gently inverting the vial a minimum of 5 times. • Allow the vial to stand at room temperature for a minimum of 15 minutes and repeat mixing by inversion. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥90% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |